Brief: Sonnet BioTherapeutics Expands Trial of SON-1010 with Atezolizumab in Advanced Ovarian Cancer
04/08/2025 14:13
Aug 4 (Reuters) - Sonnet Biotherapeutics Holdings Inc SONN.O: SONNET BIOTHERAPEUTICS EXPANDS CLINICAL EVALUATION OF SON-1010 DOSE ESCALATION WITH ATEZOLIZUMAB IN OVARIAN CANCER SONNET BIOTHERAPEUTICS HOLDINGS INC - TOPLINE DATA SHOW STRONG POTENTIAL FOR SON-1010 BENEFIT SONNET BIOTHERAPEUTICS HOLDINGS INC - TOP LINE READOUTS EXPECTED IN Q4 2025 Source text: ID:nGNX9Q2HVd Further company coverage: SONN.O ((Reuters.Briefs@thomsonreuters.com;))